Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADMA BIOLOGICS, INC.ADMA · Entity 4477 | Director | February 09, 2026 | February 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADMA BIOLOGICS, INC.
Report date February 09, 2026 · Filed February 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 263,020 |
Reported balance
After 2026-02-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-09 · Grant · Acquired 10,690 · Balance 263,020 F1: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date. F2: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; (ii) 5,445 RSUs out of 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the Reporting Person's continued service as of such vesting date; and (iii) 246,885 shares of common stock owned by the Reporting Person. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.37 · Expires 2036-02-09 | Direct | 17,730 |
Reported balance
After 2026-02-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-09 · Grant · Acquired 17,730 · Balance 17,730 F3: These options vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date.
F2: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; (ii) 5,445 RSUs out of 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the Reporting Person's continued service as of such vesting date; and (iii) 246,885 shares of common stock owned by the Reporting Person.
F3: These options vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MOMENTA PHARMACEUTICALS INC
Report date October 01, 2020 · Filed October 01, 2020
Section 16 reporting ended · disclosed 2020-10-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 1
1 source rowRow 1 · 2020-10-01 · Disposition to issuer · Disposed 160,633 · Balance 0 F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the "Merger Agreement"), by and among Johnson & Johnson, Vigor Sub, Inc. ("Merger Sub") and the Issuer, including the completion of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $52.50 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on October 1, 2020. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-10-01 · Disposition to issuer · Disposed 45,000 · Balance 0 F2: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-10-01 · Disposition to issuer · Disposed 31,500 · Balance 0 F2: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-10-01 · Disposition to issuer · Disposed 2,819 · Balance 0 F2: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-10-01 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.58 · Expires 2023-02-19 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-10-01 · Disposition to issuer · Disposed 3,572 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.96 · Expires 2024-02-18 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-10-01 · Disposition to issuer · Disposed 3,466 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.02 · Expires 2025-02-18 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-10-01 · Disposition to issuer · Disposed 6,712 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.56 · Expires 2025-08-11 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-10-01 · Disposition to issuer · Disposed 3,214 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.83 · Expires 2026-02-09 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-10-01 · Disposition to issuer · Disposed 2,363 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.85 · Expires 2027-02-07 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-10-01 · Disposition to issuer · Disposed 6,766 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.76 · Expires 2029-02-11 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2020-10-01 · Disposition to issuer · Disposed 19,344 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.87 · Expires 2030-02-07 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2020-10-01 · Disposition to issuer · Disposed 3,137 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.26 · Expires 2021-02-22 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2020-10-01 · Disposition to issuer · Disposed 8,502 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.58 · Expires 2023-02-19 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2020-10-01 · Disposition to issuer · Disposed 7,228 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.96 · Expires 2024-02-18 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2020-10-01 · Disposition to issuer · Disposed 1,356 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.02 · Expires 2025-02-18 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2020-10-01 · Disposition to issuer · Disposed 13,013 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.56 · Expires 2025-08-11 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2020-10-01 · Disposition to issuer · Disposed 6,786 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.83 · Expires 2026-02-09 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2020-10-01 · Disposition to issuer · Disposed 35,437 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.85 · Expires 2027-02-07 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2020-10-01 · Disposition to issuer · Disposed 38,334 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.76 · Expires 2029-02-11 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · 2020-10-01 · Disposition to issuer · Disposed 115,656 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.87 · Expires 2030-02-07 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 22
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 22 · 2020-10-01 · Disposition to issuer · Disposed 96,863 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the "Merger Agreement"), by and among Johnson & Johnson, Vigor Sub, Inc. ("Merger Sub") and the Issuer, including the completion of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $52.50 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on October 1, 2020. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price.
F2: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price.
F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 09, 2026 Filed Feb 12, 2026 02:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (Right to Buy) · Derivative | 17,730 | $0.00 Strike: $16.37 | $0.00 |
DisclosureSEC source: 0001140361-26-004889 · form4.xml · derivative · entry 2 KWON YOUNG · CIK 0001733094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,730 Underlying: Common Stock · 17,730 shares Expires 2036-02-09 F3 · derivative.exercise_date: These options vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. Read SEC document |
| February 09, 2026 Filed Feb 12, 2026 02:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 10,690 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-004889 · form4.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 263,020 F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date. F2 · balance_after: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; (ii) 5,445 RSUs out of 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the Reporting Person's continued service as of such vesting date; and (iii) 246,885 shares of common stock owned by the Reporting Person. Read SEC document |
| February 19, 2025 Filed Feb 22, 2025 02:05 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 16,279 | $0.00 Strike: $16.07 | $0.00 |
DisclosureSEC source: 0001140361-25-005540 · form4.xml · derivative · entry 2 KWON YOUNG · CIK 0001733094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,279 Underlying: Common Stock · 16,279 shares Expires 2035-02-19 F3 · derivative.exercise_date: The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. Read SEC document |
| February 19, 2025 Filed Feb 22, 2025 02:05 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 10,889 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-005540 · form4.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 252,330 F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date. F2 · balance_after: Includes, as of the transaction date, (i) 10,889 RSUs granted on February 19, 2025 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 12,020 RSUs granted on February 26, 2024, which will vest in full on February 26, 2024, subject to the Reporting Person's continued service as of such vesting date; and (iii) 229,421 shares of common stock owned by the reporting person. Read SEC document |
| August 23, 2024 Filed Aug 28, 2024 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | SaleCommon Stock | 60,000 | $18.26 | $1,095,600.00 |
DisclosureSEC source: 0001140361-24-038770 · form4.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 241,441 F1 · price: The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $18.25 to $18.27. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes, as of the transaction date, (i) 12,020 restricted stock units ("RSUs") granted on February 26, 2024, which will vest in full on February 26, 2025, subject to the Reporting Person's continued service as of the applicable vesting date; and (ii) 229,421 shares of common stock owned by the Reporting Person. Read SEC document |
| February 26, 2024 Filed Feb 29, 2024 02:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 37,541 | $0.00 Strike: $5.40 | $0.00 |
DisclosureSEC source: 0001140361-24-010239 · form4.xml · derivative · entry 2 KWON YOUNG · CIK 0001733094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,541 Underlying: Common Stock · 37,541 shares Expires 2034-02-26 F3 · derivative.exercise_date: The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. Read SEC document |
| February 26, 2024 Filed Feb 29, 2024 02:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 24,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-010239 · form4.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 301,441 F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date. F2 · balance_after: Includes, as of the transaction date, (i) 24,040 RSUs granted on February 26, 2024 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 25,815 RSUs granted on March 6, 2023, which will vest in full on March 6, 2024; and (iii) 251,586 shares of common stock owned by the reporting person. Read SEC document |
| August 24, 2023 Filed Aug 24, 2023 23:53 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 25,000 | $3.90 | $97,500.00 |
DisclosureSEC source: 0001140361-23-041191 · form4.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 277,401 F1 · balance_after: Includes, as of the transaction date, (i) 25,815 RSUs granted on March 6, 2023, that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date and (ii) 251,586 shares of common stock owned by the reporting person. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 02:30 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantEmployee Stock Option (right to buy) · Derivative | 51,630 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001140361-23-010768 · form4.xml · derivative · entry 2 KWON YOUNG · CIK 0001733094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,630 Underlying: Common Stock · 51,630 shares Expires 2033-03-06 F3 · derivative.exercise_date: The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 02:30 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 25,815 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-010768 · form4.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,401 F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date. F2 · balance_after: Includes, as of the transaction date, (i) 25,815 RSUs granted on March 6, 2023 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 13,293 RSUs granted on March 7, 2022, which will vest in full on March 7, 2023; and (iii) 213,293 shares of common stock owned by the reporting person. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 22:59 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantEmployee Stock Option (right to buy) · Derivative | 53,172 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001140361-22-008677 · form4.xml · derivative · entry 2 KWON YOUNG · CIK 0001733094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,172 Underlying: Common Stock · 53,172 shares Expires 2032-03-07 F3 · derivative.exercise_date: The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 22:59 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 26,586 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-008677 · form4.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,586 F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date. F2 · balance_after: Includes (i) 26,586 RSUs granted on March 7, 2022 and reported on this Form 4, subject to vesting as set forth in footnote (1); and (ii) 200,000 shares of common stock owned by the reporting person. Read SEC document |
| October 25, 2021 Filed Oct 26, 2021 11:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 100,000 | $1.00 | $100,000.00 |
DisclosureSEC source: 0001140361-21-035382 · form4.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 F1 · shares: Represents a purchase from the underwriters in the October 2021 public offering of the issuer. Read SEC document |
| October 15, 2021 Filed Oct 18, 2021 22:21 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 93,500 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001140361-21-034767 · form4.xml · derivative · entry 1 KWON YOUNG · CIK 0001733094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,500 Underlying: Common Stock · 93,500 shares Expires 2031-10-15 F1 · derivative.exercise_date: Reflects the grant of a stock option to purchase 93,500 shares of common stock, $0.0001 par value per share ("Common Stock") of ADMA Biologics, Inc. The shares of Common Stock underlying the stock option will vest in 12 equal monthly installments, becoming fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service on the applicable vesting date. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 17:05 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 96,863 | Not disclosed Strike: $31.87 | Not disclosed |
DisclosureSEC source: 0001179110-20-010056 · edgar.xml · derivative · entry 22 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 96,863 shares Expires 2030-02-07 F3 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F3 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 17:05 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 115,656 | Not disclosed Strike: $12.76 | Not disclosed |
DisclosureSEC source: 0001179110-20-010056 · edgar.xml · derivative · entry 21 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 115,656 shares Expires 2029-02-11 F3 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F3 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 17:05 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 38,334 | Not disclosed Strike: $18.85 | Not disclosed |
DisclosureSEC source: 0001179110-20-010056 · edgar.xml · derivative · entry 20 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,334 shares Expires 2027-02-07 F3 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F3 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 17:05 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 35,437 | Not disclosed Strike: $10.83 | Not disclosed |
DisclosureSEC source: 0001179110-20-010056 · edgar.xml · derivative · entry 19 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,437 shares Expires 2026-02-09 F3 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F3 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 17:05 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 6,786 | Not disclosed Strike: $21.56 | Not disclosed |
DisclosureSEC source: 0001179110-20-010056 · edgar.xml · derivative · entry 18 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,786 shares Expires 2025-08-11 F3 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F3 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 17:05 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 13,013 | Not disclosed Strike: $13.02 | Not disclosed |
DisclosureSEC source: 0001179110-20-010056 · edgar.xml · derivative · entry 17 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,013 shares Expires 2025-02-18 F3 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F3 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 17:05 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,356 | Not disclosed Strike: $17.96 | Not disclosed |
DisclosureSEC source: 0001179110-20-010056 · edgar.xml · derivative · entry 16 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,356 shares Expires 2024-02-18 F3 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F3 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 17:05 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,228 | Not disclosed Strike: $12.58 | Not disclosed |
DisclosureSEC source: 0001179110-20-010056 · edgar.xml · derivative · entry 15 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,228 shares Expires 2023-02-19 F3 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F3 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 17:05 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 8,502 | Not disclosed Strike: $13.26 | Not disclosed |
DisclosureSEC source: 0001179110-20-010056 · edgar.xml · derivative · entry 14 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,502 shares Expires 2021-02-22 F3 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F3 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 17:05 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 3,137 | Not disclosed Strike: $31.87 | Not disclosed |
DisclosureSEC source: 0001179110-20-010056 · edgar.xml · derivative · entry 13 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,137 shares Expires 2030-02-07 F3 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F3 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 17:05 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 19,344 | Not disclosed Strike: $12.76 | Not disclosed |
DisclosureSEC source: 0001179110-20-010056 · edgar.xml · derivative · entry 12 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,344 shares Expires 2029-02-11 F3 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F3 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 17:05 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 6,766 | Not disclosed Strike: $18.85 | Not disclosed |
DisclosureSEC source: 0001179110-20-010056 · edgar.xml · derivative · entry 11 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,766 shares Expires 2027-02-07 F3 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F3 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 17:05 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 2,363 | Not disclosed Strike: $10.83 | Not disclosed |
DisclosureSEC source: 0001179110-20-010056 · edgar.xml · derivative · entry 10 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,363 shares Expires 2026-02-09 F3 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F3 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 17:05 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 3,214 | Not disclosed Strike: $21.56 | Not disclosed |
DisclosureSEC source: 0001179110-20-010056 · edgar.xml · derivative · entry 9 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,214 shares Expires 2025-08-11 F3 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F3 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 17:05 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 6,712 | Not disclosed Strike: $13.02 | Not disclosed |
DisclosureSEC source: 0001179110-20-010056 · edgar.xml · derivative · entry 8 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,712 shares Expires 2025-02-18 F3 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F3 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 17:05 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 3,466 | Not disclosed Strike: $17.96 | Not disclosed |
DisclosureSEC source: 0001179110-20-010056 · edgar.xml · derivative · entry 7 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,466 shares Expires 2024-02-18 F3 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F3 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 17:05 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 3,572 | Not disclosed Strike: $12.58 | Not disclosed |
DisclosureSEC source: 0001179110-20-010056 · edgar.xml · derivative · entry 6 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,572 shares Expires 2023-02-19 F3 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F3 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 17:05 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerRestricted Stock Units · Derivative | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-010056 · edgar.xml · derivative · entry 5 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires not disclosed F2 · derivative.exercise_price: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. F2 · price: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. F2 · derivative.exercise_date: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. F2 · derivative.expiration_date: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 17:05 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerRestricted Stock Unit · Derivative | 31,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-010056 · edgar.xml · derivative · entry 4 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,500 shares Expires not disclosed F2 · derivative.exercise_price: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. F2 · price: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. F2 · derivative.exercise_date: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. F2 · derivative.expiration_date: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 17:05 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerRestricted Stock Units · Derivative | 2,819 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-010056 · edgar.xml · derivative · entry 3 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,819 shares Expires not disclosed F2 · derivative.exercise_price: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. F2 · price: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. F2 · derivative.exercise_date: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. F2 · derivative.expiration_date: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 17:05 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerRestricted Stock Unit · Derivative | 45,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-010056 · edgar.xml · derivative · entry 2 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires not disclosed F2 · derivative.exercise_price: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. F2 · price: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. F2 · derivative.exercise_date: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. F2 · derivative.expiration_date: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 17:05 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerCommon Stock | 160,633 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-010056 · edgar.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the "Merger Agreement"), by and among Johnson & Johnson, Vigor Sub, Inc. ("Merger Sub") and the Issuer, including the completion of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $52.50 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on October 1, 2020. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. Read SEC document |
| August 10, 2020 Filed Aug 11, 2020 16:41 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 652 | $32.36 | $21,098.72 |
DisclosureSEC source: 0001179110-20-008885 · edgar.xml · nonDerivative · entry 2 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,633 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 07, 2020 Filed Aug 11, 2020 16:41 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionRestricted Stock Units · Derivative | 1,410 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-008885 · edgar.xml · derivative · entry 3 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,819 Underlying: Common Stock · 1,410 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on February 7, 2017. F4 · derivative.exercise_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. F4 · derivative.expiration_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. Read SEC document |
| August 07, 2020 Filed Aug 11, 2020 16:41 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionCommon Stock | 1,410 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-008885 · edgar.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,285 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on February 7, 2017. F3 · price: Restricted Stock Units convert into common stock on a one-for-one basis. Read SEC document |
| July 20, 2020 Filed Jul 21, 2020 16:02 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 1,561 | $33.95 | $52,995.95 |
DisclosureSEC source: 0001179110-20-008395 · edgar.xml · nonDerivative · entry 2 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,875 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 17, 2020 Filed Jul 21, 2020 16:02 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionRestricted Stock Units · Derivative | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-008395 · edgar.xml · derivative · entry 3 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 Underlying: Common Stock · 3,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on October 17,2018. F4 · derivative.exercise_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. F4 · derivative.expiration_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. Read SEC document |
| July 17, 2020 Filed Jul 21, 2020 16:02 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionCommon Stock | 3,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-008395 · edgar.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,436 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on October 17,2018. F3 · price: Restricted Stock Units convert into common stock on a one-for-one basis. Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 21:15 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 6,810 | $35.11 | $239,099.10 |
DisclosureSEC source: 0001104659-20-080018 · a4.xml · nonDerivative · entry 2 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,936 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan Read SEC document |
| June 29, 2020 Filed Jul 1, 2020 21:15 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantRestricted Stock Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-080018 · a4.xml · derivative · entry 3 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of MNTA Common Stock. F4 · derivative.exercise_date: Subject to the officer's continued employment with the company, 15,000 Restricted Stock Units will vest on June 29, 2021. F4 · derivative.expiration_date: Subject to the officer's continued employment with the company, 15,000 Restricted Stock Units will vest on June 29, 2021. Read SEC document |
| June 29, 2020 Filed Jul 1, 2020 21:15 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-080018 · a4.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,746 F1 · kind: Shares received pursuant to settlement of Performance Stock Units that were granted on October 17, 2018. Read SEC document |
| June 12, 2020 Filed Jun 15, 2020 17:21 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 6,756 | $30.15 | $203,693.40 |
DisclosureSEC source: 0001179110-20-007356 · edgar.xml · nonDerivative · entry 2 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,746 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 17:21 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantRestricted Stock Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-007356 · edgar.xml · derivative · entry 3 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of MNTA Common Stock. F4 · derivative.exercise_date: Subject to the officer's continued employment with the company, 15,000 Restricted Stock Units will vest on June 11, 2021. F4 · derivative.expiration_date: Subject to the officer's continued employment with the company, 15,000 Restricted Stock Units will vest on June 11, 2021. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 17:21 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-007356 · edgar.xml · nonDerivative · entry 1 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,502 F1 · kind: Shares received pursuant to settlement of Performance Stock Units that were granted on October 17, 2018. Read SEC document |
| May 08, 2020 Filed May 11, 2020 16:20 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 629 | $33.30 | $20,945.70 |
DisclosureSEC source: 0001179110-20-005717 · edgar.xml · nonDerivative · entry 2 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,502 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 07, 2020 Filed May 11, 2020 16:20 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionRestricted Stock Units · Derivative | 1,409 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005717 · edgar.xml · derivative · entry 3 KWON YOUNG · CIK 0001733094 · Chief Financial & Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,229 Underlying: Common Stock · 1,409 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on February 7, 2017. F4 · derivative.exercise_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. F4 · derivative.expiration_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.